Julio Rosenstock, MD, FACE, is the lead author of an article published today in the Oxford University Press’ Endocrine Reviews Journal. Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a similar risk of hypoglycemia. It also highlights the clinical rationale and potential benefits of these weekly insulins and discusses the limitations and challenges the molecules could pose in clinical practice.
Read the article: https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnad037/7550051
